TRAIN 2 Trial: BluePrint predicts response to neoadjuvant pertuzumab in HER2-positive
Breast Cancer Research 25, Article Number: 71 (2023) Authors: Liefaard et al.
Read MoreBreast Cancer Research 25, Article Number: 71 (2023) Authors: Liefaard et al.
Read More